Company Encyclopedia
View More
name
AHWB
301520.SZ
Anhui Wanbang Pharmaceutical Technology Co.,Ltd. provides drug research and development and clinical trial services for drug manufacturers and marketing authorization holders in China. The company was founded in 2006 and is based in Hefei, China.
550.52 B
301520.SZMarket value -Rank by Market Cap -/-

Financial Score

06/12/2025 Update
C
Life Sciences Tools and ServicesIndustry
Industry Ranking21/27
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE2.70%C
    • Profit Margin13.84%B
    • Gross Margin20.33%D
  • Growth ScoreE
    • Revenue YoY-25.16%E
    • Net Profit YoY-62.38%D
    • Total Assets YoY-0.54%D
    • Net Assets YoY0.28%C
  • Cash ScoreD
    • Cash Flow Margin722.78%B
    • OCF YoY-25.16%E
  • Operating ScoreD
    • Turnover0.19D
  • Debt ScoreA
    • Gearing Ratio4.93%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    AHWB released its performance for the first three quarters, with a net profit attributable to the parent company of 33.1106 million yuan, a decrease of 57.44%

    AHWB released its third-quarter report for 2025, with operating revenue of 209 million yuan in the first three quarters, a year-on-year decrease of 28.60%. The net profit attributable to the parent company was 33.1106 million yuan, a year-on-year decline of 57.44%; the net profit after deducting non-recurring gains and losses was 8.4492 million yuan, a year-on-year decrease of 84.89%. The basic earnings per share were 0.5 yuan

    Zhitong·
    SZ
    301520
    +1.43%
    Zhitong·
    SZ
    301520
    +1.43%

    The innovative drug concept fell at the beginning of the session, with Cosunter down 10%

    The innovative drug concept opened lower, with Cosunter down 10%, and Qianhong Bio-pharma, PKU HEALTHCARE, AHWB, Hicin Pharmaceutical, and Ruizhi Pharmaceutical all opening lower collectively

    Zhitong·
    SZ
    002550
    +0.25%
    SZ
    000788
    -2.26%
    SZ
    301520
    +1.43%
    Zhitong·
    SZ
    002550
    +0.25%
    SZ
    000788
    -2.26%
    SZ
    301520
    +1.43%

    The medical services sector has seen a short-term decline, with Kingchem falling over 8%

    The medical services sector has seen a short-term decline, with Kingchem dropping over 8%, followed by PR, Bio-S, HitGen, and AHWB

    Zhitong·
    SZ
    301096
    +2.48%
    SH
    688222
    +1.15%
    SZ
    301520
    +1.43%
    Zhitong·
    SZ
    301096
    +2.48%
    SH
    688222
    +1.15%
    SZ
    301520
    +1.43%

    Ergothioneine receives attention, multiple listed companies respond to related questions

    Ergothioneine has recently attracted market attention, with several listed companies responding to related questions on interactive platforms. CITIC Securities' research report points out that ergothioneine has promising prospects in synthetic biology new materials. LEAGUER's equity investee, Ruidelin, has obtained Self-GRAS certification for ergothioneine; AHWB is collaborating with Sanofi on clinical projects; Shouxiangu's ergothioneine has natural antioxidant properties; Fuerjia's products contain ergothioneine ingredients

    Zhitong·
    SZ
    301371
    +0.58%
    SZ
    301520
    +1.43%
    SH
    603896
    +0.20%
    Zhitong·
    SZ
    301371
    +0.58%
    SZ
    301520
    +1.43%
    SH
    603896
    +0.20%

    AHWB released its 2024 annual performance, with a net profit attributable to the parent company of 85.5307 million yuan, a decrease of 20.87%

    AHWB released its 2024 annual report, with operating revenue of 379 million yuan, a year-on-year increase of 10.91%. The net profit attributable to shareholders was 85.5307 million yuan, a year-on-year decrease of 20.87%; the net profit after deducting non-recurring gains and losses was 55.7878 million yuan, a year-on-year decrease of 42.90%. The basic earnings per share were 1.28 yuan

    Zhitong·
    SZ
    301520
    +1.43%
    Zhitong·
    SZ
    301520
    +1.43%
    © 2025 Longbridge｜Disclaimer